secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001601830-24-000199
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion & Exscientia shareholders approve combination; close expected Nov 20
------------------------------------------------------------------------------

- Overwhelming shareholder approval from both Recursion (RXRX) and Exscientia (EXAI) for the proposed combination.
- Transaction expected to close on November 20, 2024, subject to remaining customary conditions.
- Chris Gibson, Ph.D., to remain CEO of the combined company post-closing.
- Update call on Nov 20 at 7:30 a.m. ET; details on X, LinkedIn, YouTube.
- Final voting results to be filed via 8-K and 6-K with SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000199/0001601830-24-000199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000199/rxrx-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer